Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 19, 2017
Pharmacy Choice - Pharmaceutical News - Generic Drugs to Slow Growth of Antifungal Market [Daily News Egypt] - October 19, 2017

Pharmacy News Article

 3/17/17 - Generic Drugs to Slow Growth of Antifungal Market [Daily News Egypt]

(GlobeNewswire) - New proprietary research by BCC Research predicts that new and innovative antifungal drugs in development, along with a growing number of people with weakened immune systems and FDA fast-track provisions, are aiding growth in the global market for antifungal drugs.

BCC Research`s Antifungal Drugs: Technologies and Global Markets expects the global market for antifungal drugs to reach $16.1 billion in 2021, up from $13.1 billion in 2016.

Research Highlights

Fungal infestations in humans, animals, plants and the environment are on the rise, with many having lethal consequences in both the immunocompetent and the immunocompromised.

Asia-Pacific should lead all regions with an anticipated 9.9% CAGR.

Merck & Co. is the largest market share holder for all antifungal drugs in the global market.

"While the North American market remains the largest geographic region by value, the Asia-Pacific region is the driver of the global market," says BCC Research Editorial Director Kevin Fitzgerald. "BCC Research predicts that region and North America to account for 24.9% and 36.9% of the global market in 2021, respectively."

Innovative Products in Development Pipeline

Although no new antifungal drug classes have emerged, many products are under development, including VL-2397, a novel antifungal drug initially developed by Vical Incorporated partner, Astellas Pharma; PC945, a novel triazole anti-fungal (inhaled treatment) for pulmonary aspergillosis; and CD101 IV, a novel molecule of antifungals for the treatment of systemic Candida infections.

"A lack of funding and development of new and innovative antifungal drug classes has restrained the market," says Fitzgerald. In the last 30 years, only one new class of antifungal drugs, echinocandins, has been developed. Whatever the reason for this paucity, the need for new, improved, and affordable antifungal treatments with greater safety and efficacy is clear."

About BCC Research

BCC Research is a publisher of market research reports that provide organizations with intelligence to drive smart business decisions. By partnering with industry experts worldwide, BCC Research provides unbiased measurements and assessments of global markets covering major industrial and technology sectors, including emerging markets. For more information about BCC Research, please visit Follow BCC Research on Twitter at @BCCResearch.

Editors and reporters who wish to speak with the analyst should contact Steven Cumming at

(c) 2017 Daily News Egypt. Provided by SyndiGate Media Inc. (

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Oct 19: Type II Diabetes: Case Studies and Management Options
Oct 23: Vitamin D Primer for Pharmacy Professionals
Oct 24: Metabolic Syndrome: The Heart of Any Wellness Practice
Oct 25: Dispensing Controlled Substances in Today’s Pharmacy
Oct 26: Management of Schizophrenia & Acute Agitation
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement